The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas

Malignant gliomas are devastating neoplasia with limited curative treatment options. Temozolomide (TMZ, Temcat(®), Temodal(®) or Temodar(®)) is a first-line treatment for malignant gliomas but the development of drug resistance remains a major concern. Activating transcription factor 4 (ATF4) is a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Daishi, Rauh, Manfred, Buchfelder, Michael, Eyupoglu, Ilker Y., Savaskan, Nicolai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584239/
https://www.ncbi.nlm.nih.gov/pubmed/28881638
http://dx.doi.org/10.18632/oncotarget.17737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584239/
https://www.ncbi.nlm.nih.gov/pubmed/28881638
http://dx.doi.org/10.18632/oncotarget.17737

Ejemplares similares